US FDA strengthens renal warnings for diabetes products

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2016年 / 1607卷 / 1期

关键词：

D O I：

10.1007/s40278-016-18580-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：6 / 6

相关论文

共 50 条

[31] US FDA recommendations on cardio risk in diabetes trials
Reactions Weekly, 2009, 1234 (1) : 2 - 2
[32] Risk Management Policy and Black-Box Warnings A Qualitative Analysis of US FDA Proceedings
Cook, Daniel M.
Gurugubelli, Rama K.
Bero, Lisa A.
DRUG SAFETY, 2009, 32 (11) : 1057 - 1066
[33] FDA orders stronger warnings on benzodiazepines
Demarinis, Susie
EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2021, 17 (01) : 4 - 4
[34] FDA wants warnings on Enbrel label
Reactions Weekly, 2008, 1208 (1) : 2 - 2
[35] The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin
Anand K.
Sketris I.
Zhang Y.
Levy A.
Gamble J.-M.
Drugs - Real World Outcomes, 2017, 4 (4) : 215 - 223
[36] Fluoroquinolones: strengthened warnings requested by FDA
Reactions Weekly, 2008, 1210 (1) : 3 - 3
[37] FDA strengthens labelling for cardiovascular risks of glitazones
Reactions Weekly, 2002, 900 (1) : 2 - 2
[38] FDA implements safeguards to prevent contaminated products in US market
Reactions Weekly, 2023, 1948 (1) : 2 - 2
[39] US FDA recalls Hyland's belladonna teething products
Reactions Weekly, 2017, 1649 (1) : 5 - 5
[40] Marketing of unapproved drug products must stop - US FDA
Reactions Weekly, 2008, 1222 (1) : 4 - 4

← 1 2 3 4 5 →